NEW YORK, Sept 12 (Reuters) - King Pharmaceuticals Inc KG.N said on Wednesday it would seek a rehearing with the U.S. federal appeals court that ruled the patent on King’s biggest product, the high blood pressure medicine Altace, was invalid.
The decision by the U.S. Court of Appeals for the Federal Circuit, which reversed a lower court ruling, would allow the sale of cheaper generic versions of the medicine known chemically as ramipril.
King said the court’s finding that the Altace patent was invalid on the basis of obviousness is not consistent with other recent rulings of the Federal Circuit Court. The company also said it believes Tuesday’s appeals court decision relied on factual inaccuracies. (Reporting by Bill Berkrot)